Sunnova Energy International
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2K
- Market Cap
- -
- Introduction
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company’s goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
An Investigation of Psilocybin on Behavioural and Cognitive Symptoms of Adults With Fragile X Syndrome
- Conditions
- Cognitive DysfunctionFragile X SyndromeBehavior
- Interventions
- Drug: Psilocybin, 1.5 mg
- First Posted Date
- 2023-04-27
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- Nova Mentis Life Science Corp
- Target Recruit Count
- 10
- Registration Number
- NCT05832255
- Locations
- 🇨🇦
KGK Science Inc., London, Ontario, Canada
Establishing a Diagnostic and Therapeutic Index in Autism Spectrum Disorder (ASD) and Fragile X Syndrome
- Conditions
- Fra(X) SyndromeAutism Spectrum Disorder
- First Posted Date
- 2021-05-03
- Last Posted Date
- 2021-10-13
- Lead Sponsor
- Nova Mentis Life Science Corp
- Target Recruit Count
- 300
- Registration Number
- NCT04869930
- Locations
- 🇺🇸
Broward Health Medical Center, Fort Lauderdale, Florida, United States
News
Ultra-Processed Foods Linked to 17% Higher Type 2 Diabetes Risk in Large European Study
A landmark EPIC study of over 311,000 participants reveals that each 10% increase in ultra-processed food consumption raises type 2 diabetes risk by 17% over 11 years of follow-up.